EMEA-002296-PIP01-17-M03

Invented name	Alunbrig
Active substance	brigatinib
Therapeutic area	Oncology
Decision number	P/0405/2021
PIP number	EMEA-002296-PIP01-17-M03
Pharmaceutical form(s)	Age-appropriate liquid dosage form Film-coated tablet
Condition(s) / indication(s)	Treatment of anaplastic large cell lymphoma Treatment of inflammatory myofibroblastic tumours Treatment of non-small cell lung cancer
Route(s) of administration	Oral use
Contact for public enquiries	Takeda Pharm A/S E-mail: medinfoEMEA@takeda.com Tel. +44 (0)3333 000181
Decision type	PM: decision on the application for modification of an agreed PIP

Add your rating

★ ★ ★ ★ ★